Dr. Anke Mueller-Fahrnow is the Chair of the Conscience Board of Directors, the Chair of the SGC (Structural Genomics Consortium) Board of Directors, and she works as an independent consultant for a German contract research organization, Nuvisan ICB GmbH. Trained as a biochemist and structural biologist at the Free University of Berlin, Anke has 30 years of experience in pharmaceutical drug discovery. She began her career as a bench scientist and transitioned to managerial positions with increasing levels of responsibility. She retired from Bayer as Vice President, Lead Discovery Berlin.
Early on in her career, Anke became interested in public-private partnerships. Together with scientists from pharma and academia, she conceptualized, planned, managed and led multi-million dollar programs for the Innovative Medicines Initiative (IMI) of the European Union. Her research interests include drug discovery, particularly in the areas of oncology and women’s health. She has published close to 50 scientific publications. Anke is a strong supporter of public science, aiming to make research results broadly available in the public domain to foster drug discovery, especially in areas of unmet medical needs.
